Glucose is an important energy source for our cancer-killing T cells. In kidney tumors, however, poor nutrient conditions often disrupt T cell metabolism and inhibit their anti-cancer activity. Dr. Beckermann is characterizing how exactly the tumor environment perturbs T cell metabolism. Then, using patients’ cells and mouse models, she’s developing approaches to support T cells and restore their normal metabolism. The insights she uncovers might then suggest ways to target and improve the effectiveness of these anti-cancer T cells in immunotherapies for patients.
Vanderbilt University | Breast Cancer, Kidney Cancer, Lung Cancer, Melanoma | 2016 | Jeffrey Rathmell, Ph.D.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
Cancer is not “one-size-fits-all” and neither are its treatments, especially when it comes to immunotherapy. Learn how CRI is helping more people overcome cancer.
Immunotherapy updates from the world's largest cancer conference, the Annual Meeting of the American Society for Clinical Oncology (ASCO).